Fillable Online Puma biotechnology, inc. form s-1/a - Biotech Due Diligence Fax Email Print - pdfFiller
PBYI Insider Trading Activity - Puma Biotechnology, Inc.
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Can Puma Biotechnology Inc (PBYI) Stock Rise to the Top of Healthcare Sector Tuesday?
Puma Biotechnology
Puma Biotechnology, Inc. | LinkedIn
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology, Inc. (PBYI) Company Information - Simply Wall St
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Exhibitor Puma Biotechnology 07-10 - Scripps CME Connection
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Former Puma Biotechnology Executive Sentenced to More than Two Years in Prison for Insider Trading | BioSpace
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology Surging
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology (PBYI) - 5 Price Charts 2012-2023 (History)
